These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11828840)

  • 21. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 22. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post marketing surveillance of new drugs. Patient safety in the hands of GPs.
    Marley JE
    Aust Fam Physician; 1989 Sep; 18(9):1133-5. PubMed ID: 2590077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug surveillance: the concept, the need and methods].
    Moreno González A
    An R Acad Nac Med (Madr); 1992; 109(1):197-218; discussion 218-20. PubMed ID: 1463138
    [No Abstract]   [Full Text] [Related]  

  • 25. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacologic surveillance and safety of drugs: reflexions for legislative and, especially, cultural action].
    Laporte JR
    Rev Med Univ Navarra; 1988; 32(1):31-3. PubMed ID: 3154929
    [No Abstract]   [Full Text] [Related]  

  • 28. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 29. Reforms on drug safety.
    Nature; 2006 Sep; 443(7110):372. PubMed ID: 17006474
    [No Abstract]   [Full Text] [Related]  

  • 30. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
    MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
    JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The 1990 drug law. Its implications for the clinical doctor].
    Castillo Pérez P; Gutiérrez López JF
    Med Clin (Barc); 1992 Feb; 98(7):263-9. PubMed ID: 1560703
    [No Abstract]   [Full Text] [Related]  

  • 32. [More transparency in drug safety].
    Saussele T
    Med Monatsschr Pharm; 2009 Sep; 32(9):325. PubMed ID: 19795694
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 34. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 35. Contributing to drug safety.
    Johnson JM
    Am J Hosp Pharm; 1990 Jun; 47(6):1280. PubMed ID: 2368721
    [No Abstract]   [Full Text] [Related]  

  • 36. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S; Bryant SG; Kluge RM
    Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug regulation 2056.
    Bezold C; Peck J
    Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091
    [No Abstract]   [Full Text] [Related]  

  • 38. Regulatory decisions and consumers.
    Rawlins MD
    Med Toxicol; 1986; 1 Suppl 1():128-9. PubMed ID: 3821428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indication creep: physician beware.
    Hébert PC; Stanbrook M
    CMAJ; 2007 Sep; 177(7):697, 699. PubMed ID: 17823137
    [No Abstract]   [Full Text] [Related]  

  • 40. The drug safety review process.
    Somberg J
    Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.